DMARD

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Retrieved on: 
星期四, 一月 4, 2024
Marketing, BAL, PV, INN, Risk, MPA, Shivering, DLBCL, CD20, BLL, PML, Pemphigus vulgaris, Cancer, Inflammation, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Nose, Ageing, Allergy, Glucocorticoid, CLL, NHL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Overview, B cell, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, Lymphocytosis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Medical Subject Headings, Marketing, Arava, European Commission, Arthritis, INN, Risk, ATC, Joint, Hepatotoxicity, DMARD, International, European, Disease, Language, Rheumatoid arthritis, Inflammation, Disease-modifying antirheumatic drug, Lymphocyte, Tablet, Select, Committee, Patient, Risk management, Anatomy, Medicine, Psoriatic arthritis, Methotrexate, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Pemphigus, Allergy, B cell, Hepatitis B virus, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Language, Blood, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, Autoimmune disease, TNF, CHOP, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, PV, INN, Risk, MPA, Shivering, CD20, PML, Pemphigus vulgaris, Inflammation, Infection, Anatomy, Lymphoma, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Nose, Allergy, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, B cell, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, TNF, INN, Immune system, Etanercept, Ulcerative colitis, Adolescence, Caregiver, PUVA, ATC, Joint, Crohn's disease, Psoriatic arthritis, Bleeding, International, Headache, Disease, Common, Ageing, Nose, Language, Arthritis, Inflammation, Hypersensitivity, Allergy, Disease-modifying antirheumatic drug, European Medicines Agency, Ulcer, Select, Anatomy, Methotrexate, IIA, DMARD, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Liver, Marketing, MP, Heart, MRI, INN, Risk, MTX, Pneumonia, Fungus, AZA, UC, Eating, Inflammation, Ankylosing spondylitis, Infection, Fungal infection, Diagnosis, Anatomy, Ulcer, Lymphoma, IIA, Skin, Vasculitis, Yeast, Psoriasis, ATC, Joint, Pain, Psoriatic arthritis, Syringe, Disease, Nose, Allergy, Lower respiratory tract infection, Nonsteroidal anti-inflammatory drug, Hepatitis B virus, Safety, Heart failure, CRP, Disorder, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Leukemia, Patient, Medical Subject Headings, Walking, Immune system, Ulcerative colitis, International, Arthritis, Language, Blood, Hepatitis B, Medication package insert, Tuberculosis, Select, Medicine, Methotrexate, Azathioprine, TNF, X-ray, Mercaptopurine, European Medicines Agency, Spine, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, BAL, PV, INN, Risk, MPA, Shivering, DLBCL, Pemphigus, CD20, BLL, PML, Pemphigus vulgaris, Cancer, Inflammation, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Bone marrow, GPA, Nose, Ageing, Allergy, Glucocorticoid, CLL, NHL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, Lymphocytosis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Mymee's Personalized Trial & Care Platform Helps Autoimmune Disease Patients Reverse Flares, New Research Shows

Retrieved on: 
星期二, 五月 16, 2023
Trigger, Long COVID, Factorization of polynomials, Flare, DMARD, Elijah Cummings Lower Drug Costs Now Act, Rx, Arthralgia, Anxiety, Case Western Reserve University School of Medicine, RMD, Quality of life, Research, COVID, Pain, DMTS, DSM-IV codes, Medical director, Patient, Risk, Autoimmune disease, OTC, Joint, HIPAA, Autoimmunity, Fatigue, Pharmaceutical industry, Nursing, Medical device, Medical imaging, Birth control, Rheumatology, Quality of life (healthcare), Medicine

NEW YORK, May 16, 2023 /PRNewswire/ -- Today Mymee Inc, the pioneer in personalized trial & care for autoimmune disease & long COVID patients, announced the publication of new peer-reviewed research in RMD Open. The study found that autoimmune disease and Long COVID patients with moderate to severe symptoms achieved statistically significant, clinically meaningful improvements in all10 PROMIS® Health-Related Quality of Life (HRQoL) domains.

Key Points: 
  • The bigger challenge is that >65% of rheumatic patients have inadequate response to autoimmune drugs in the real world.
  • The personalized trial process helps patients directly correlate symptoms to triggers, add back activities, manage sensitivities and adjust drugs with their physician, if necessary.
  • Key characteristics and findings from Mymee's personalized trial research included:
    Reversing flares: >85% of patients with moderate to severe symptoms saw improvements in HRQoL.
  • For more information on Mymee's research and personalized trial & care platform to help autoimmune Rx non-responders reverse uncontrolled flares, please visit www.mymee.com

Pharmascience Canada launches pms-APREMILAST, a generic drug with multiple indications

Retrieved on: 
星期二, 一月 17, 2023
Methotrexate, Tablet, Safety, Psoriasis, Apremilast, Patient, Light, DMARD, Pharmaceutical industry

MONTREAL, Jan. 17, 2023 /CNW Telbec/ - Pharmascience Canada is pleased to launch pms-APREMILAST, only in 30 mg tablets in Canada.

Key Points: 
  • MONTREAL, Jan. 17, 2023 /CNW Telbec/ - Pharmascience Canada is pleased to launch pms-APREMILAST, only in 30 mg tablets in Canada.
  • This is a generic equivalent of the product Otezla®.
  • "Pharmascience is pleased to add the first generic equivalent of Otezla® to our product portfolio.
  • As Canada's largest drug manufacturer, we remain committed to providing patients with a safe and cost-effective option for the treatment of their condition"- Mike Dutton, Vice President, and General Manager of Pharmascience Canada.